The key differentiator between the physIQ platform and other technologies is that it constructs a personalized baseline norm for each person monitored, rather than simple trending or comparison to population-based statistics. In September 2023, Telemetrix and physIQ announced the launch of HealthTracer, LLC to provide cutting-edge continuous remote patient monitoring services utilizing the physIQ platform for high acuity patients and advanced analytics. The company is strategically positioned at the intersection of clinical validation, regulatory compliance, and emerging digital biomarker technology.
Cyborg Score Rationale
PhysIQ has established clinical validation, FDA clearance, and strategic partnerships with major healthcare systems, but faces capital constraints as a smaller private company ($15M revenue, 66 employees) competing in a growing but crowded remote monitoring market. Acquisition by Prolaio adds operational uncertainty around independence and growth trajectory.
Top Insights
The company has published one of the most rigorous clinical studies to date in digital medicine and are pioneers in developing, validating, and achieving regulatory approval of Artificial Intelligence-based analytics.
The physIQ annual revenue was $15.1 million in 2025.
PhysIQ has 66 total employees.
PhysIQ was acquired by Prolaio.
Named Competitors
Empatica — Wearable technology and health monitoring platform for clinical research and patient care
Byteflies — Telemonitoring solutions for remote vital sign measurements and analysis in healthcare
Biofourmis — Digital therapeutics and remote monitoring platform for chronic disease management
Kinesis Health Technologies — Digital health platform for remote patient monitoring and clinical outcomes
Recent Developments
(September 2023) Launched HealthTracer, LLC joint venture with Telemetrix for integrated remote patient monitoring within EHR systems
(Announced date not specified) Collaboration announced with clinical-stage biopharma InCarda Therapeutics for inhaled cardiovascular disease therapies
(Date not specified) Appointed John Wilson as SVP and General Manager of Life Sciences and Chris Englerth as VP of Marketing
Open the full interactive PhysIQ, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.